基本情報
- CAS
28797-61-7- 標準SMILES
CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1- InChIKey
RMHMFHUVIITRHF-UHFFFAOYSA-N- 分子式
- C19H21N5O2
- 平均分子量
- 351.4 g/mol
- 単同位体質量
- 351.16952493
概要
Pirenzepine is a pyridobenzodiazepine. It has a role as a muscarinic antagonist, an anti-ulcer drug and an antispasmodic drug.
名称と識別子
- 優先名称
- Pirenzepine
- IUPAC
- 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
- 現地名
- ピレンゼピン二塩酸塩一水和物
- 英語名
- Pirenzepine
- 分子式
- C19H21N5O2
- 分子量
- 351.4
名称と別名
pirenzepine28797-61-7PirenzepinPirenzepinaPirenzepinum11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-oneDTXSID7023487ACI-9111-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-oneWST-05711-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-oneLS-519
名称をさらに表示
5,11-ジヒドロ-11-[(4-メチル-1-ピペラジニル)アセチル]-6H-ピリド[2,3-b][1,4]ベンゾジアゼピン-6-オンピレンゼピンピレンゼピン二塩酸塩一水和物2-[2-(4-メチルピペラジン-1-イル)アセチル]-2,4,9-トリアザトリシクロ[9.4.0.03,8]ペンタデカ-1(15),3,5,7,11,13-ヘキサエン-10-オンLS-519-C12Gastrozepinnyl)acetyl)-Tabe：UlcufortonPirenzepineBasePirenzepine dihydrocPirenzepine USP/EP/BPOmbitasvir Impurity 2
3G0285N20NCHEBI:8247DTXCID3034876H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((4-methyl-1-piperazinyl)acetyl)-Pyrenzepine6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-LS 519Piren basan
物性
構造計算による物性
- XLogP
- 0.1
- 極性表面積
- 68.8 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 5
- 回転可能結合数
- 2
- 重原子数
- 26
- 形式電荷
- 0
- 複雑度
- 534
実験および物理化学的性質
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals
LogP
0.6
0.1
Solubility6.82e-01 g/L
Physical DescriptionSolid
Collision Cross Section187.76 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 沸点
- 541.7 · 541.7±50.0 °C(Predicted)
- 比重(密度)
- 1.271 · 1.271±0.06 g/cm3(Predicted)
- 貯蔵温度
- Store at RT
- 溶解性
- soluble in No data available
- 酸解離定数(Pka)
- 11.29 · 11.29±0.20(Predicted)
- 外見
- solid
- 色
- white
- 水溶解度
- 100 mM · water: 100mM
- InChI
- 1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS ClassificationNot Classified
危険有害性情報
Regulatory InformationREACH registered substance: Pirenzepine (EC: 249-228-4)
Other Safety InformationIMAP assessments - 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-: Environment tier I assessment
Hazard Classes and CategoriesNot Classified
安全データ
- wgk
- WGK 2
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
ATC Code
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Pharmacodynamics
Pirenzepine belongs to a group of medications called antispasmodics/anticholinergics. These medications are used to relieve cramps or spasms of the stomach, intestines, and bladder. Pirenzepine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.
Mechanism of Action
Pirenzepine is a muscarinic receptor antagonist and binds to the muscarinic acetylcholine receptor. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
MeSH Pharmacological Classification
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
Cellular LocationsMembrane
Metabolite PathwaysPirenzepine Action Pathway
用途と製造
UsesUse (kg; approx.) in Germany (2009): >100
関連反応
1 件
化合物ノート
読み込み中…